BEATcc: Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer
Atezolizumab plus bevacizumab and chemotherapy for
metastatic, persistent, or recurrent cervical cancer (BEATcc)
Study Summaries
GOG 281: Trametinib in recurrent low-grade serous ovarian cancer
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer.
MIRASOL: Mirvetuximab in Platinum Resistant Cancer
Mirvetuximab Soravtansine (MIRV) in platinum resistant ovarian cancer
EORTC-55994: Neoadjuvant Chemotherapy Followed by Surgery vs. Chemoradiation in Locally Advanced Cervical Cancer
EORTC and the trial from TATA memorial. Is neoadjuvant chemotherapy and surgery an alternative to chemoradiation in locally advanced cervical cancer?
DUO-E: Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib in Advanced Endometrial Cancer
Does adding durvalumab (a PD-L1 inhibitor) and olaparib (a PARP inhibitor) to standard chemotherapy improve outcomes in advanced or recurrent endometrial cancer?
OUTBACK Trial: Chemotherapy after Chemoradiation
OUTBACK trial